Candel Therapeutics, Inc.
CADL
$9.79
$0.323.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.65M | 4.93M | 4.90M | 4.34M | 4.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.28M | 15.75M | 13.21M | 11.18M | 8.13M |
| Operating Income | -16.28M | -15.75M | -13.21M | -11.18M | -8.13M |
| Income Before Tax | -8.86M | -29.50M | -11.27M | -4.80M | 7.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.86M | -29.50M | -11.27M | -4.80M | 7.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.86M | -29.50M | -11.27M | -4.80M | 7.38M |
| EBIT | -16.28M | -15.75M | -13.21M | -11.18M | -8.13M |
| EBITDA | -16.14M | -15.58M | -13.01M | -10.94M | -7.89M |
| EPS Basic | -0.14 | -0.54 | -0.21 | -0.09 | 0.15 |
| Normalized Basic EPS | -0.09 | -0.34 | -0.13 | -0.06 | 0.09 |
| EPS Diluted | -0.14 | -0.54 | -0.21 | -0.09 | 0.13 |
| Normalized Diluted EPS | -0.09 | -0.34 | -0.13 | -0.06 | 0.08 |
| Average Basic Shares Outstanding | 62.36M | 54.90M | 54.89M | 51.49M | 50.48M |
| Average Diluted Shares Outstanding | 62.36M | 54.90M | 54.89M | 51.49M | 54.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |